Studies show that plant-based diets can help lower prostate-specific antigen (PSA levels), improve serum testosterone and erectile dysfunction.
A team of Beaumont Health researchers from Radiology, Radiation Oncology and Urology studied the relationship between benign prostatic hyperplasia, or BPH, and prostate cancer in 405 men by quantitatively looking at different parts of prostate tissue on MRI.
University Hospitals offers a new technique called PrecisionPoint Transperineal Access System for obtaining a prostate biopsy. The hospital will also conduct a clinical trial to determine if it offers greater benefits than a traditional biopsy.
Nearly 10 million cancer screenings in the U.S. failed to happen because of the COVID-19 pandemic, according to a study published in JAMA Oncology, a publication of the American Medical Association.
The Mount Sinai Hospital is the first academic center in the Northeast region to teach Aquablation® therapy—a robotically guided advanced new therapy and minimally invasive procedure used to treat enlarged prostates, a common condition technically known as benign prostatic hyperplasia (BPH). The teaching program is being led by Steven A. Kaplan, MD, Professor of Urology, Icahn School of Medicine at Mount Sinai and Director of the Men’s Wellness Program, Mount Sinai Health System.
A new year brings a new opportunity to focus on health, and Loyola Medicine Men’s Health Center Director Kevin McVary, MD is offering tips for a healthier 2021.
Research by a University of Georgia scientist sheds light on how two genes factor into prostate cancer cells becoming resistant to treatment, providing a potential new target for therapeutics.
In mid-October, Baylor Scott & White Medical Center – Temple conducted its 1000th holmium laser enucleation of the prostate (HoLEP), a minimally invasive procedure that can address benign prostatic hyperplasia (BPH). BPH can prevent the bladder from emptying properly and could lead to kidney damage or failure. It also impacts quality of life in about one third of men older than 50 years old.
While prostate cancer originates within the prostate, metastasis, or the spread of a tumor from the site of origin to other organs, remains a leading cause of death among people with the disease. Prostate tumors can metastasize to a number of different organs, including the liver, lymph nodes and bone.
Study reports 98% sensitivity and 97% specificity in recognizing and characterizing prostate cancer using an artificial intelligence (AI) program.
During the COVID-19 pandemic, Johns Hopkins Medicine Media Relations is focused on disseminating current, accurate and useful information to the public via the media. As part of that effort, we are distributing our “COVID-19 Tip Sheet: Story Ideas from Johns Hopkins” every Tuesday throughout the duration of the outbreak.
For decades, therapy to strengthen pelvic muscles has been the standard treatment for men dealing with urinary incontinence after prostate surgery. But a new study suggests that may not be the best approach.
A research study published in the journal Neoplasia and led by principal investigator Nallasivam Palanisamy, Ph.D., associate scientist in the Vattikuti Urology Institute at Henry Ford Health System, has identified a novel prostate cancer gene fusion involving the KLK4 protein coding gene and KLKP1 pseudogene. This unique biomarker can be detected in the urine samples of patients with prostate cancer, offering a non-invasive means of detection.